Article Details
Retrieved on: 2022-08-13 07:48:26
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Raymond James downgraded Landos Biopharma Inc (NASDAQ: LABP) to Market Perform from Outperform following 2Q22 earnings and the first look at NX-13 ...
Article found on: www.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here